Delivering a 33% p.a. total return over the last decade, Medistim has been a successful European compounder by dominating its niche. I will explore if it still has its best days ahead of it.
I very agree with your conclusions, I see it as a possible portfolio guardian at the appropriate multiples and waiting a possible expansion at other markets.
I very agree with your conclusions, I see it as a possible portfolio guardian at the appropriate multiples and waiting a possible expansion at other markets.
If I look at the employee split, they have 1/4 of total people in the US...mostly sales.
How can they possibly be more agressive in that area?
Thanks a lot again! I also had Medistim on my radar but it didnt Flash me enough. Would appreciate an analysis for Eurofins :)
-17% today 🧐